Observations placeholder

Ipilimumab (trade name Yervoy, formerly known as MDX-010 and MDX-101), is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to function.

Ipilimumab is approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma, a type of skin cancer. It is undergoing clinical trials for the treatment of non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC) bladder cancer and metastatic hormone-refractory prostate cancer.

Adverse effects

Ipilimumab treatment has been associated with severe and potentially fatal immunological adverse effects due to T cell activation and proliferation. Most of the serious adverse effects are associated with the gastro-intestinal tract; they include stomach pain, bloating, constipation or diarrhea, but also fever, breathing or urinating problems. A "risk evaluation and mitigation strategy" informs prescribers of the potential risks.

On Jan, 27, 2016: 1,494 people reported to have side effects when taking Yervoy. Among them, 5 people (0.33%) have Hallucination.

Time on Yervoy when people have Hallucination  :

Gender of people who have Hallucination when taking Yervoy  :

On Feb, 1, 2016: 1,494 people reported to have side effects when taking Yervoy. Among them, 252 people (16.87%) have Death.

Time on Yervoy when people have Death  :

Gender of people who have Death when taking Yervoy  :

Age of people who have Death when taking Yervoy :

Top conditions involved for these people :

1. Malignant melanoma (56 people, 22.22%)
2. Metastatic malignant melanoma (33 people, 13.10%)
3. Metastasis (2 people, 0.79%)